Clinical trial results:
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, sixteen-armed, parallel group, multi-centre, multinational trial with liraglutide 3.0 mg as active comparator

Summary

EudraCT number	2014-001540-38
Trial protocol	BE DE GB
Global end of trial date	12 April 2017

Results information

Result version number	v1 (current)
This version publication date	22 April 2018
First version publication date	22 April 2018

Trial information

Trial identification

Sponsor protocol code	NN9536-4153

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02453711
WHO universal trial number (UTN)	U1111-1155-4660

Notes:

Sponsors

Sponsor organisation name	Novo Nordisk A/S
Sponsor organisation address	Novo Allé, Bagsvaerd, Denmark, 2880
Public contact	Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S, clinicaltrials@novonordisk.com
Scientific contact	Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S, clinicaltrials@novonordisk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 October 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 March 2017
Global end of trial reached?	Yes
Global end of trial date	12 April 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess and compare the dose-response of five doses of once-daily semaglutide versus placebo in inducing and maintaining weight loss after 52 weeks in obese subjects without diabetes mellitus

Protection of trial subjects:

The trial was conducted in accordance with the Declaration of Helsinki (October 2013), ICH Good Clinical Practice (June 1996), Europäische Norm (EN) International Organization for Standardization (ISO) 14155 Part 1 and 2 and 21 United States (US) Code of Federal Regulations (CFR) 312.120.

Background therapy:

Not applicable.

Evidence for comparator:

Not applicable.

Actual start date of recruitment	01 October 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 56
Country: Number of subjects enrolled	Belgium: 96
Country: Number of subjects enrolled	Canada: 75
Country: Number of subjects enrolled	Germany: 69
Country: Number of subjects enrolled	Israel: 83
Country: Number of subjects enrolled	Russian Federation: 124
Country: Number of subjects enrolled	United Kingdom: 113
Country: Number of subjects enrolled	United States: 341
Worldwide total number of subjects	957
EEA total number of subjects	278

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	882
From 65 to 84 years	74
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The trial was conducted at 71 sites in 8 countries as follows: Australia: 5, Belgium: 5, Canada: 9, Germany: 6, Israel: 7, Russian Federation: 10, United Kingdom (UK): 8, United States (US): 21. Along with this, recruitment of subjects was planned at 3 sites (1 each in Germany, Russian Federation, and US), but where no subjects were screened.

Pre-assignment

Screening details:

Design:Subjects were randomised to 1 of the 16 parallel treatment arms in a 6:1 ratio (active:placebo) to receive either:
A)Semaglutide 0.05/0.1/0.2/0.3/0.4 mg; dose escalation every fourth week
B)Semaglutide 0.3/0.4 mg; dose escalation every second week
C)Liraglutide 3.0 mg;dose escalation every week
D)Placebo;matching each of the active treatment

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Subjects were centrally randomised to 1 of the 16 parallel treatment arms using interactive web response system (IWRS). Semaglutide and corresponding placebo as well as liraglutide and corresponding placebo were supplied in similar pen systems and were by all means visually identical and were packed and labelled to fulfil the requirements for double-blind procedures. Furthermore, equal volumes of active substance and placebo were administered during treatment ensuring blinding within dose level

Arms

Are arms mutually exclusive?	Yes
Arm title	Semaglutide 0.05 mg

Arm description:

Subjects received once daily semaglutide 0.05 mg subcutaneous (s.c.; under the skin) injections for 52 weeks.

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Semaglutide 0.1 mg

Arm description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).

Arm type	Experimental

Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Semaglutide 0.2 mg

Arm description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Semaglutide 0.3 mg

Arm description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Semaglutide 0.4 mg

Arm description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Semaglutide 0.3 mg (fast escalation)

Arm description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and

4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Semaglutide 0.4 mg (fast escalation)

Arm description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide 1.0 mg/mL injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Liraglutide 3.0 mg

Arm description:

Subjects received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.

Arm type	Active comparator
Investigational medicinal product name	Liraglutide
Investigational medicinal product code	
Other name	Saxenda®
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Liraglutide 6.0 mg/mL injections were administered using pre-filled PDS290 pen-injector in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Arm title	Placebo pool

Arm description:

Subjects received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).

Arm type	Placebo
Investigational medicinal product name	Semaglutide placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide placebo injections were administered using NovoPen® 4 in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Investigational medicinal product name	Liraglutide placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Liraglutide placebo injections were administered using pre-filled PDS290 pen-injector in the thigh, abdomen or upper arm daily and were to the extent possible to be administered on the same time every day.

Number of subjects in period 1	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg
Started	103	102	103
Completed	92	95	94
Not completed	11	7	9
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	5	4	6
Unclassified	1	-	1
Lost to follow-up	5	3	2

Number of subjects in period 1	Semaglutide 0.3 mg	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)
Started	103	102	102
Completed	96	100	96
Not completed	7	2	6
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	4	1	1
Unclassified	-	-	-
Lost to follow-up	3	1	5

Number of subjects in period 1	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg	Placebo pool
Started	103	103	136
Completed	100	96	123
Not completed	3	7	13
Adverse event, serious fatal	1	-	-
Consent withdrawn by subject	-	1	7
Unclassified	-	-	-
Lost to follow-up	2	6	6

Baseline characteristics

Reporting groups	
Reporting group title	Semaglutide 0.05 mg
Reporting group description:	
Subjects received once daily semaglutide 0.05 mg subcutaneous (s.c.; under the skin) injections for 52 weeks.	
Reporting group title	Semaglutide 0.1 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).	
Reporting group title	Semaglutide 0.2 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).	
Reporting group title	Semaglutide 0.3 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).	
Reporting group title	Semaglutide 0.4 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).	
Reporting group title	Semaglutide 0.3 mg (fast escalation)
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).	
Reporting group title	Semaglutide 0.4 mg (fast escalation)
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).	
Reporting group title	Liraglutide 3.0 mg
Reporting group description:	
Subjects received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.	
Reporting group title	Placebo pool
Reporting group description:	
Subjects received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).	

Reporting group values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg
Number of subjects	103	102	103
Age Categorical			
Results are based on the full analysis set (FAS), which included all randomised subjects.			
Units: Subjects			
Adults (18-64 years)	93	93	99

From 65-84 years	10	9	4
85 years and over	0	0	0

Age Continuous			
Results are based on the FAS.			
Units: years			
arithmetic mean	46.97	45.24	44.37
standard deviation	± 12.80	± 12.62	± 11.24
Gender Categorical			
Results are based on the FAS.			
Units: Subjects			
Female	67	66	66
Male	36	36	37
Body weight			
Results are based on the FAS.			
Units: Kg			
arithmetic mean	111.29	111.31	114.49
standard deviation	± 23.17	± 21.47	± 24.53
Glycosylated haemoglobin (HbA1c)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.1 mg treatment arm' = 101.			
Units: Percentage (%) of HbA1c			
arithmetic mean	5.51	5.45	5.41
standard deviation	± 0.35	± 0.43	± 0.39
Fasting plasma glucose (FPG)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.4 mg treatment arm' = 101.			
Units: mmol/L			
arithmetic mean	5.48	5.48	5.41
standard deviation	± 0.64	± 0.55	± 0.77

Reporting group values	Semaglutide 0.3 mg	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)
Number of subjects	103	102	102
Age Categorical			
Results are based on the full analysis set (FAS), which included all randomised subjects.			
Units: Subjects			
Adults (18-64 years)	97	86	95
From 65-84 years	6	16	7
85 years and over	0	0	0
Age Continuous			
Results are based on the FAS.			
Units: years			
arithmetic mean	46.73	48.37	47.10
standard deviation	± 12.02	± 13.44	± 12.05
Gender Categorical			
Results are based on the FAS.			
Units: Subjects			
Female	66	66	66
Male	37	36	36

Body weight			
Results are based on the FAS.			
Units: Kg			
arithmetic mean	111.51	113.20	108.11
standard deviation	± 22.96	± 26.42	± 22.08
Glycosylated haemoglobin (HbA1c)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.1 mg treatment arm' = 101.			
Units: Percentage (%) of HbA1c			
arithmetic mean	5.51	5.47	5.48
standard deviation	± 0.38	± 0.42	± 0.41
Fasting plasma glucose (FPG)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.4 mg treatment arm' = 101.			
Units: mmol/L			
arithmetic mean	5.48	5.40	5.43
standard deviation	± 0.73	± 0.67	± 0.64

Reporting group values	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg	Placebo pool
Number of subjects	103	103	136
Age Categorical			
Results are based on the full analysis set (FAS), which included all randomised subjects.			
Units: Subjects			
Adults (18-64 years)	95	97	127
From 65-84 years	7	6	9
85 years and over	1	0	0
Age Continuous			
Results are based on the FAS.			
Units: years			
arithmetic mean	46.07	48.50	46.42
standard deviation	± 13.51	± 11.22	± 12.80
Gender Categorical			
Results are based on the FAS.			
Units: Subjects			
Female	67	67	88
Male	36	36	48
Body weight			
Results are based on the FAS.			
Units: Kg			
arithmetic mean	109.56	108.71	114.19
standard deviation	± 21.33	± 21.94	± 25.37
Glycosylated haemoglobin (HbA1c)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.1 mg treatment arm' = 101.			
Units: Percentage (%) of HbA1c			
arithmetic mean	5.49	5.53	5.54
standard deviation	± 0.42	± 0.38	± 0.38
Fasting plasma glucose (FPG)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.4 mg treatment arm' = 101.			
Units: mmol/L			
arithmetic mean	5.54	5.55	5.50

standard deviation	± 0.87	± 0.73	± 0.62

Reporting group values	Total		
Number of subjects	957		
Age Categorical			
Results are based on the full analysis set (FAS), which included all randomised subjects.			
Units: Subjects			
Adults (18-64 years)	882		
From 65-84 years	74		
85 years and over	1		
Age Continuous			
Results are based on the FAS.			
Units: years			
arithmetic mean			
standard deviation	-		
Gender Categorical			
Results are based on the FAS.			
Units: Subjects			
Female	619		
Male	338		
Body weight			
Results are based on the FAS.			
Units: Kg			
arithmetic mean			
standard deviation	-		
Glycosylated haemoglobin (HbA1c)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.1 mg treatment arm' = 101.			
Units: Percentage (%) of HbA1c			
arithmetic mean			
standard deviation	-		
Fasting plasma glucose (FPG)			
Results are based on the FAS. Number of subjects analysed in 'Semaglutide 0.4 mg treatment arm' = 101.			
Units: mmol/L			
arithmetic mean			
standard deviation	-		

End points

End points reporting groups

Reporting group title	Semaglutide 0.05 mg
Reporting group description:	
Subjects received once daily semaglutide 0.05 mg subcutaneous (s.c.; under the skin) injections for 52 weeks.	
Reporting group title	Semaglutide 0.1 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).	
Reporting group title	Semaglutide 0.2 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).	
Reporting group title	Semaglutide 0.3 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).	
Reporting group title	Semaglutide 0.4 mg
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).	
Reporting group title	Semaglutide 0.3 mg (fast escalation)
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).	
Reporting group title	Semaglutide 0.4 mg (fast escalation)
Reporting group description:	
Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).	
Reporting group title	Liraglutide 3.0 mg
Reporting group description:	
Subjects received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.	
Reporting group title	Placebo pool
Reporting group description:	
Subjects received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).	

Primary: Relative change from baseline in body weight (%)

End point title	Relative change from baseline in body weight (%)
End point description:	
Relative change from baseline (week 0) in body weight was evaluated after 52 weeks of treatment. Results are based on the full analysis set (FAS), which included all randomised subjects. Number of subjects analysed = number of subjects contributed to the analysis. Following mentioned 'measure type'	

should be read as ‘Least Square Mean’. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate.

End point type	Primary

End point timeframe:

At 52 weeks

End point values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg	Semaglutide 0.3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	92	96	94	95
Units: Percentage (%)				
number (not applicable)	-5.99	-8.62	-11.60	-11.17

End point values	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	95	100	96
Units: Percentage (%)				
number (not applicable)	-13.84	-11.38	-16.29	-7.76

End point values	Placebo pool			
Subject group type	Reporting group			
Number of subjects analysed	123			
Units: Percentage (%)				
number (not applicable)	-2.29			

Statistical analyses

Statistical analysis title	Semaglutide 0.05 mg versus Placebo Pool

Statistical analysis description:

J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett’s method was used to adjust for multiple comparisons. The following ‘comparison groups’ should be read as 'semaglutide 0.05 mg - placebo pool'.

Comparison groups	Semaglutide 0.05 mg v Placebo pool

Number of subjects included in analysis	215
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0055
Method	ANCOVA
Parameter estimate	Treatment difference (%-points)
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.55
upper limit	-0.85

Statistical analysis title	Semaglutide 0.1 mg versus placebo pool

Statistical analysis description:

J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett's method was used to adjust for multiple comparisons. The following 'comparison groups' should be read as 'semaglutide 0.1 mg - placebo pool'.

Comparison groups	Semaglutide 0.1 mg v Placebo pool
Number of subjects included in analysis	219
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Treatment difference (%-points)
Point estimate	-6.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.16
upper limit	-3.49

Statistical analysis title	Semaglutide 0.2 mg versus placebo pool

Statistical analysis description:

J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett's method was used to adjust for multiple comparisons. The following 'comparison groups' should be read as 'semaglutide 0.2 mg - placebo pool'.

Comparison groups	Semaglutide 0.2 mg v Placebo pool
Number of subjects included in analysis	217
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Treatment difference (%-points)
Point estimate	-9.31

Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.15
upper limit	-6.46

Statistical analysis title	Semaglutide 0.3 mg versus placebo pool

Statistical analysis description:

J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett's method was used to adjust for multiple comparisons. The following 'comparison groups' should be read as 'semaglutide 0.3 mg - placebo pool'.

Comparison groups	Semaglutide 0.3 mg v Placebo pool
Number of subjects included in analysis	218
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Treatment difference (%-points)
Point estimate	-8.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.72
upper limit	-6.03

Statistical analysis title	Semaglutide 0.4 mg versus placebo pool

Statistical analysis description:

J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett's method was used to adjust for multiple comparisons. The following 'comparison groups' should be read as 'semaglutide 0.4 mg - placebo pool'.

Comparison groups	Semaglutide 0.4 mg v Placebo pool
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Treatment difference (%-points)
Point estimate	-11.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.38
upper limit	-8.72

Secondary: Proportion (%) of subjects with weight loss of ≥ 5% of baseline body weight

End point title	Proportion (%) of subjects with weight loss of ≥ 5% of baseline body weight

End point description:

Proportion of subjects who lost more than or equal to 5% of their baseline (week 0) body weight was evaluated after 52 weeks of treatment. Results are based on the FAS, which included all randomised subjects. Following mentioned 'measure type' should be read as 'Least Square Mean'. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate.

End point type	Secondary

End point timeframe:

At 52 weeks

End point values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg	Semaglutide 0.3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	92	96	94	95
Units: Percentage (%) of subjects				
number (not applicable)	53.50	67.49	74.91	80.52

End point values	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	95	100	96
Units: Percentage (%) of subjects				
number (not applicable)	82.52	72.19	89.58	66.12

End point values	Placebo pool			
Subject group type	Reporting group			
Number of subjects analysed	123			
Units: Percentage (%) of subjects				
number (not applicable)	22.87			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion (%) of subjects with weight loss of ≥ 10% of baseline body

End point title	Proportion (%) of subjects with weight loss of ≥ 10% of baseline body

End point description:

Proportion of subjects who lost more than or equal to 10% of their baseline (week 0) body weight was evaluated after 52 weeks of treatment. Results are based on the FAS, which included all randomised subjects. Number of subjects analysed = number of subjects contributed to the analysis. Following mentioned 'measure type' should be read as 'Least Square Mean'. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate.

End point type	Secondary

End point timeframe:

At 52 weeks

End point values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg	Semaglutide 0.3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	92	96	94	95
Units: Percentage (%) of subjects				
number (not applicable)	18.94	36.57	55.95	57.76

End point values	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	95	100	96
Units: Percentage (%) of subjects				
number (not applicable)	64.61	58.45	71.91	33.98

End point values	Placebo pool			
Subject group type	Reporting group			
Number of subjects analysed	123			
Units: Percentage (%) of subjects				
number (not applicable)	10.08			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in body weight (kg)

End point title	Change in body weight (kg)

End point description:

Change from baseline (week 0) in body weight was evaluated after 52 weeks of treatment. Results are based on the FAS, which included all randomised subjects. Number of subjects analysed = number of subjects contributed to the analysis. Following mentioned 'measure type' should be read as 'Least Square Mean'. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate.

End point type	Secondary

End point timeframe:

From baseline to 52 weeks

End point values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg	Semaglutide 0.3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	92	96	94	95
Units: Kg				
number (not applicable)	-6.66	-9.34	-12.30	-12.45

End point values	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100	95	100	96
Units: Kg				
number (not applicable)	-15.15	-12.54	-17.36	-8.47

End point values	Placebo pool			
Subject group type	Reporting group			
Number of subjects analysed	123			
Units: Kg				
number (not applicable)	-2.48			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in glycosylated haemoglobin (HbA1c)

End point title	Change in glycosylated haemoglobin (HbA1c)

End point description:

Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment. Results are based on the FAS, which included all randomised subjects. Number of subjects analysed = number of subjects contributed to the analysis. Following mentioned 'measure type' should be read as 'Least Square Mean'. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a

jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline HbA1c as covariate.

End point type	Secondary

End point timeframe:

From baseline to 52 weeks

End point values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg	Semaglutide 0.3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	77	88	87	87
Units: Percentage (%) of HbA1c				
number (not applicable)	-0.13	-0.21	-0.28	-0.23

End point values	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	82	75	91	85
Units: Percentage (%) of HbA1c				
number (not applicable)	-0.29	-0.25	-0.34	-0.21

End point values	Placebo pool			
Subject group type	Reporting group			
Number of subjects analysed	103			
Units: Percentage (%) of HbA1c				
number (not applicable)	-0.01			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in fasting plasma glucose (FPG)

End point title	Change in fasting plasma glucose (FPG)

End point description:

Change from baseline (week 0) in FPG was evaluated after 52 weeks of treatment. Results are based on the FAS, which included all randomised subjects. Number of subjects analysed = number of subjects contributed to the analysis. Following mentioned ‘measure type’ should be read as ‘Least Square Mean’. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline FPG as covariate.

End point type	Secondary

End point timeframe:
From baseline to 52 weeks

End point values	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg	Semaglutide 0.3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	77	88	86	88
Units: mmol/L				
number (not applicable)	-0.29	-0.35	-0.40	-0.39

End point values	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	81	75	91	86
Units: mmol/L				
number (not applicable)	-0.43	-0.38	-0.51	-0.35

End point values	Placebo pool			
Subject group type	Reporting group			
Number of subjects analysed	103			
Units: mmol/L				
number (not applicable)	0.01			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Week 0 up to Week 59 (treatment period: week 0 to week 52 + follow-up period: week 53 to week 59). Number of deaths causally related to treatment' is the data considered to present under 'total number of deaths resulting from adverse events'.

Adverse event reporting additional description:

All AEs mentioned here are treatment-emergent adverse events (TEAEs), which was defined as any AE reported after first trial product administration and until last trial product administration with a 7-week follow-up period. Results are based on the safety analysis set, which included all subjects receiving at least 1 dose of randomised treatment.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19

Reporting groups

Reporting group title	Semaglutide 0.05 mg

Reporting group description:

Subjects received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.

Reporting group title	Semaglutide 0.1 mg

Reporting group description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).

Reporting group title	Semaglutide 0.2 mg

Reporting group description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).

Reporting group title	Semaglutide 0.3 mg

Reporting group description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).

Reporting group title	Semaglutide 0.4 mg

Reporting group description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).

Reporting group title	Semaglutide 0.3 mg (fast escalation)

Reporting group description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).

Reporting group title	Semaglutide 0.4 mg (fast escalation)

Reporting group description:

Subjects received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).

Reporting group title	Liraglutide 3.0 mg

Reporting group description:

Subjects received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.

Reporting group title	Placebo pool

Reporting group description:

Subjects received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).

Serious adverse events	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 103 (12.62%)	8 / 102 (7.84%)	5 / 103 (4.85%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bowen's disease			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer metastatic			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell cancer of the renal pelvis and ureter			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular insufficiency			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Cardiac pacemaker insertion			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrectomy			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Percutaneous coronary intervention			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food allergy			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Reproductive system and breast disorders			
Endometrial hyperplasia			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometriosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma-chronic obstructive pulmonary disease overlap syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Human chorionic gonadotropin increased			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle enzyme increased			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Fall			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Very long-chain acyl-coenzyme A dehydrogenase deficiency			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina pectoris			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cauda equina syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Vestibular disorder			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal scarring			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic cyst			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hand dermatitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Livedo reticularis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Haematuria			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress urinary incontinence			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 103 (0.00%)	2 / 102 (1.96%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Lumbar spinal stenosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	3 / 103 (2.91%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 103 (0.97%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis infective			

subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Escherichia coli			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			

subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obesity			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Semaglutide 0.3 mg	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 103 (5.83%)	13 / 102 (12.75%)	6 / 102 (5.88%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bowen's disease			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer metastatic			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell cancer of the renal pelvis and ureter			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular insufficiency			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Cardiac pacemaker insertion			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrectomy			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Percutaneous coronary intervention			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food allergy			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Endometrial hyperplasia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometriosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma-chronic obstructive pulmonary disease overlap syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Human chorionic gonadotropin increased			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle enzyme increased			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Congenital, familial and genetic disorders			
Very long-chain acyl-coenzyme A dehydrogenase deficiency			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cauda equina syndrome			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vestibular disorder			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal scarring			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic cyst			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	2 / 102 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	3 / 102 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hand dermatitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Livedo reticularis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress urinary incontinence			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Back pain			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Appendicitis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis infective			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Escherichia coli			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			

subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 103 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obesity			
subjects affected / exposed	0 / 103 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg	Placebo pool
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 103 (6.80%)	4 / 103 (3.88%)	11 / 136 (8.09%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bowen's disease			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			

subjects affected / exposed	0 / 103 (0.00%)	1 / 103 (0.97%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer metastatic			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell cancer of the renal pelvis and ureter			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular insufficiency			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Cardiac pacemaker insertion			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrectomy			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Percutaneous coronary intervention			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food allergy			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Endometrial hyperplasia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometriosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma-chronic obstructive pulmonary disease overlap syndrome			

subjects affected / exposed	0 / 103 (0.00%)	1 / 103 (0.97%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Human chorionic gonadotropin increased			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle enzyme increased			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture			
subjects affected / exposed	0 / 103 (0.00%)	1 / 103 (0.97%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Road traffic accident			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Very long-chain acyl-coenzyme A dehydrogenase deficiency			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cauda equina syndrome			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vestibular disorder			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal scarring			

subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic cyst			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			

Hand dermatitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Livedo reticularis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress urinary incontinence			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 103 (0.97%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			

subjects affected / exposed	0 / 103 (0.00%)	1 / 103 (0.97%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	1 / 136 (0.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis infective			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Escherichia coli			

subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	0 / 136 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obesity			
subjects affected / exposed	0 / 103 (0.00%)	0 / 103 (0.00%)	2 / 136 (1.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Semaglutide 0.05 mg	Semaglutide 0.1 mg	Semaglutide 0.2 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	83 / 103 (80.58%)	87 / 102 (85.29%)	84 / 103 (81.55%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 103 (0.00%)	6 / 102 (5.88%)	1 / 103 (0.97%)
occurrences (all)	0	6	1
Lipase increased			
subjects affected / exposed	2 / 103 (1.94%)	2 / 102 (1.96%)	2 / 103 (1.94%)
occurrences (all)	2	2	2
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	4 / 103 (3.88%)	1 / 102 (0.98%)	2 / 103 (1.94%)
occurrences (all)	4	1	2
Nervous system disorders			
Dizziness			
subjects affected / exposed	3 / 103 (2.91%)	6 / 102 (5.88%)	9 / 103 (8.74%)
occurrences (all)	3	6	9
Headache			
subjects affected / exposed	7 / 103 (6.80%)	15 / 102 (14.71%)	10 / 103 (9.71%)
occurrences (all)	9	20	12
General disorders and administration site conditions			
Early satiety			
subjects affected / exposed	3 / 103 (2.91%)	4 / 102 (3.92%)	5 / 103 (4.85%)
occurrences (all)	3	4	5
Fatigue			
subjects affected / exposed	4 / 103 (3.88%)	7 / 102 (6.86%)	7 / 103 (6.80%)
occurrences (all)	4	7	7
Injection site bruising			
subjects affected / exposed	3 / 103 (2.91%)	5 / 102 (4.90%)	5 / 103 (4.85%)
occurrences (all)	4	5	8
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 103 (0.00%)	3 / 102 (2.94%)	6 / 103 (5.83%)
occurrences (all)	0	3	7
Abdominal distension			

subjects affected / exposed	3 / 103 (2.91%)	7 / 102 (6.86%)	4 / 103 (3.88%)
occurrences (all)	3	8	6
Abdominal pain			
subjects affected / exposed	5 / 103 (4.85%)	3 / 102 (2.94%)	16 / 103 (15.53%)
occurrences (all)	8	6	18
Abdominal pain upper			
subjects affected / exposed	2 / 103 (1.94%)	4 / 102 (3.92%)	6 / 103 (5.83%)
occurrences (all)	2	4	6
Constipation			
subjects affected / exposed	13 / 103 (12.62%)	22 / 102 (21.57%)	26 / 103 (25.24%)
occurrences (all)	15	27	33
Diarrhoea			
subjects affected / exposed	20 / 103 (19.42%)	25 / 102 (24.51%)	35 / 103 (33.98%)
occurrences (all)	29	37	60
Dyspepsia			
subjects affected / exposed	3 / 103 (2.91%)	8 / 102 (7.84%)	6 / 103 (5.83%)
occurrences (all)	5	8	8
Eructation			
subjects affected / exposed	4 / 103 (3.88%)	8 / 102 (7.84%)	14 / 103 (13.59%)
occurrences (all)	4	13	20
Flatulence			
subjects affected / exposed	4 / 103 (3.88%)	4 / 102 (3.92%)	3 / 103 (2.91%)
occurrences (all)	4	4	4
Gastrooesophageal reflux disease			
subjects affected / exposed	8 / 103 (7.77%)	9 / 102 (8.82%)	8 / 103 (7.77%)
occurrences (all)	8	9	8
Nausea			
subjects affected / exposed	32 / 103 (31.07%)	42 / 102 (41.18%)	45 / 103 (43.69%)
occurrences (all)	41	80	74
Vomiting			
subjects affected / exposed	8 / 103 (7.77%)	18 / 102 (17.65%)	24 / 103 (23.30%)
occurrences (all)	10	29	41
Respiratory, thoracic and mediastinal disorders			
Cough			

subjects affected / exposed	5 / 103 (4.85%)	5 / 102 (4.90%)	3 / 103 (2.91%)
occurrences (all)	5	5	3
Oropharyngeal pain			
subjects affected / exposed	2 / 103 (1.94%)	8 / 102 (7.84%)	3 / 103 (2.91%)
occurrences (all)	2	9	4
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 103 (0.97%)	3 / 102 (2.94%)	1 / 103 (0.97%)
occurrences (all)	1	3	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 103 (0.97%)	0 / 102 (0.00%)	6 / 103 (5.83%)
occurrences (all)	1	0	6
Insomnia			
subjects affected / exposed	3 / 103 (2.91%)	6 / 102 (5.88%)	2 / 103 (1.94%)
occurrences (all)	3	6	2
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	7 / 103 (6.80%)	9 / 102 (8.82%)	6 / 103 (5.83%)
occurrences (all)	9	13	7
Back pain			
subjects affected / exposed	8 / 103 (7.77%)	11 / 102 (10.78%)	6 / 103 (5.83%)
occurrences (all)	17	16	6
Infections and infestations			
Bronchitis			
subjects affected / exposed	4 / 103 (3.88%)	5 / 102 (4.90%)	4 / 103 (3.88%)
occurrences (all)	6	5	6
Gastroenteritis			
subjects affected / exposed	5 / 103 (4.85%)	11 / 102 (10.78%)	6 / 103 (5.83%)
occurrences (all)	7	15	6
Influenza			
subjects affected / exposed	2 / 103 (1.94%)	10 / 102 (9.80%)	4 / 103 (3.88%)
occurrences (all)	2	14	6
Nasopharyngitis			
subjects affected / exposed	16 / 103 (15.53%)	23 / 102 (22.55%)	19 / 103 (18.45%)
occurrences (all)	20	26	24

Sinusitis			
subjects affected / exposed	4 / 103 (3.88%)	5 / 102 (4.90%)	7 / 103 (6.80%)
occurrences (all)	6	7	10
Upper respiratory tract infection			
subjects affected / exposed	12 / 103 (11.65%)	10 / 102 (9.80%)	13 / 103 (12.62%)
occurrences (all)	16	12	17
Urinary tract infection			
subjects affected / exposed	3 / 103 (2.91%)	6 / 102 (5.88%)	4 / 103 (3.88%)
occurrences (all)	3	6	5
Viral infection			
subjects affected / exposed	5 / 103 (4.85%)	6 / 102 (5.88%)	3 / 103 (2.91%)
occurrences (all)	5	8	3
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	8 / 103 (7.77%)	17 / 102 (16.67%)	13 / 103 (12.62%)
occurrences (all)	8	17	14

Non-serious adverse events	Semaglutide 0.3 mg	Semaglutide 0.4 mg	Semaglutide 0.3 mg (fast escalation)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	85 / 103 (82.52%)	90 / 102 (88.24%)	91 / 102 (89.22%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 103 (0.00%)	5 / 102 (4.90%)	0 / 102 (0.00%)
occurrences (all)	0	7	0
Lipase increased			
subjects affected / exposed	0 / 103 (0.00%)	6 / 102 (5.88%)	4 / 102 (3.92%)
occurrences (all)	0	7	4
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	3 / 103 (2.91%)	4 / 102 (3.92%)	2 / 102 (1.96%)
occurrences (all)	3	5	2
Nervous system disorders			
Dizziness			
subjects affected / exposed	4 / 103 (3.88%)	9 / 102 (8.82%)	8 / 102 (7.84%)
occurrences (all)	4	11	9
Headache			

subjects affected / exposed	10 / 103 (9.71%)	20 / 102 (19.61%)	14 / 102 (13.73%)
occurrences (all)	12	31	17
General disorders and administration site conditions			
Early satiety			
subjects affected / exposed	3 / 103 (2.91%)	6 / 102 (5.88%)	3 / 102 (2.94%)
occurrences (all)	3	6	3
Fatigue			
subjects affected / exposed	7 / 103 (6.80%)	13 / 102 (12.75%)	9 / 102 (8.82%)
occurrences (all)	7	15	10
Injection site bruising			
subjects affected / exposed	5 / 103 (4.85%)	6 / 102 (5.88%)	5 / 102 (4.90%)
occurrences (all)	10	6	5
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	2 / 103 (1.94%)	3 / 102 (2.94%)	6 / 102 (5.88%)
occurrences (all)	2	4	6
Abdominal distension			
subjects affected / exposed	2 / 103 (1.94%)	6 / 102 (5.88%)	8 / 102 (7.84%)
occurrences (all)	2	7	10
Abdominal pain			
subjects affected / exposed	8 / 103 (7.77%)	9 / 102 (8.82%)	8 / 102 (7.84%)
occurrences (all)	10	11	8
Abdominal pain upper			
subjects affected / exposed	6 / 103 (5.83%)	4 / 102 (3.92%)	6 / 102 (5.88%)
occurrences (all)	6	5	7
Constipation			
subjects affected / exposed	18 / 103 (17.48%)	24 / 102 (23.53%)	19 / 102 (18.63%)
occurrences (all)	25	35	23
Diarrhoea			
subjects affected / exposed	27 / 103 (26.21%)	38 / 102 (37.25%)	28 / 102 (27.45%)
occurrences (all)	54	62	52
Dyspepsia			
subjects affected / exposed	14 / 103 (13.59%)	14 / 102 (13.73%)	15 / 102 (14.71%)
occurrences (all)	24	17	16
Eructation			

subjects affected / exposed	8 / 103 (7.77%)	7 / 102 (6.86%)	17 / 102 (16.67%)
occurrences (all)	12	7	21
Flatulence			
subjects affected / exposed	3 / 103 (2.91%)	6 / 102 (5.88%)	8 / 102 (7.84%)
occurrences (all)	3	9	10
Gastrooesophageal reflux disease			
subjects affected / exposed	7 / 103 (6.80%)	10 / 102 (9.80%)	10 / 102 (9.80%)
occurrences (all)	8	11	13
Nausea			
subjects affected / exposed	43 / 103 (41.75%)	49 / 102 (48.04%)	55 / 102 (53.92%)
occurrences (all)	69	94	106
Vomiting			
subjects affected / exposed	11 / 103 (10.68%)	17 / 102 (16.67%)	21 / 102 (20.59%)
occurrences (all)	18	34	32
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	6 / 103 (5.83%)	2 / 102 (1.96%)	3 / 102 (2.94%)
occurrences (all)	6	2	3
Oropharyngeal pain			
subjects affected / exposed	1 / 103 (0.97%)	4 / 102 (3.92%)	5 / 102 (4.90%)
occurrences (all)	1	4	6
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	6 / 103 (5.83%)	1 / 102 (0.98%)	1 / 102 (0.98%)
occurrences (all)	6	1	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 103 (1.94%)	1 / 102 (0.98%)	2 / 102 (1.96%)
occurrences (all)	3	1	2
Insomnia			
subjects affected / exposed	1 / 103 (0.97%)	3 / 102 (2.94%)	2 / 102 (1.96%)
occurrences (all)	1	3	2
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 103 (3.88%)	7 / 102 (6.86%)	4 / 102 (3.92%)
occurrences (all)	4	8	5

Back pain			
subjects affected / exposed	9 / 103 (8.74%)	3 / 102 (2.94%)	7 / 102 (6.86%)
occurrences (all)	10	3	7
Infections and infestations			
Bronchitis			
subjects affected / exposed	7 / 103 (6.80%)	3 / 102 (2.94%)	3 / 102 (2.94%)
occurrences (all)	7	3	3
Gastroenteritis			
subjects affected / exposed	8 / 103 (7.77%)	10 / 102 (9.80%)	4 / 102 (3.92%)
occurrences (all)	9	11	4
Influenza			
subjects affected / exposed	10 / 103 (9.71%)	2 / 102 (1.96%)	5 / 102 (4.90%)
occurrences (all)	13	2	5
Nasopharyngitis			
subjects affected / exposed	15 / 103 (14.56%)	19 / 102 (18.63%)	16 / 102 (15.69%)
occurrences (all)	20	26	18
Sinusitis			
subjects affected / exposed	3 / 103 (2.91%)	6 / 102 (5.88%)	5 / 102 (4.90%)
occurrences (all)	3	6	6
Upper respiratory tract infection			
subjects affected / exposed	10 / 103 (9.71%)	11 / 102 (10.78%)	10 / 102 (9.80%)
occurrences (all)	15	16	11
Urinary tract infection			
subjects affected / exposed	6 / 103 (5.83%)	2 / 102 (1.96%)	4 / 102 (3.92%)
occurrences (all)	6	2	5
Viral infection			
subjects affected / exposed	3 / 103 (2.91%)	4 / 102 (3.92%)	3 / 102 (2.94%)
occurrences (all)	3	4	3
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	13 / 103 (12.62%)	14 / 102 (13.73%)	18 / 102 (17.65%)
occurrences (all)	14	14	21

Non-serious adverse events	Semaglutide 0.4 mg (fast escalation)	Liraglutide 3.0 mg	Placebo pool
Total subjects affected by non-serious adverse events			
subjects affected / exposed	88 / 103 (85.44%)	83 / 103 (80.58%)	87 / 136 (63.97%)

Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 103 (2.91%)	1 / 103 (0.97%)	1 / 136 (0.74%)
occurrences (all)	3	1	1
Lipase increased			
subjects affected / exposed	1 / 103 (0.97%)	3 / 103 (2.91%)	1 / 136 (0.74%)
occurrences (all)	1	4	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 103 (0.97%)	0 / 103 (0.00%)	7 / 136 (5.15%)
occurrences (all)	1	0	14
Nervous system disorders			
Dizziness			
subjects affected / exposed	7 / 103 (6.80%)	7 / 103 (6.80%)	2 / 136 (1.47%)
occurrences (all)	8	8	2
Headache			
subjects affected / exposed	11 / 103 (10.68%)	15 / 103 (14.56%)	15 / 136 (11.03%)
occurrences (all)	13	22	19
General disorders and administration site conditions			
Early satiety			
subjects affected / exposed	3 / 103 (2.91%)	4 / 103 (3.88%)	2 / 136 (1.47%)
occurrences (all)	3	4	2
Fatigue			
subjects affected / exposed	7 / 103 (6.80%)	5 / 103 (4.85%)	9 / 136 (6.62%)
occurrences (all)	7	6	9
Injection site bruising			
subjects affected / exposed	6 / 103 (5.83%)	4 / 103 (3.88%)	9 / 136 (6.62%)
occurrences (all)	8	4	27
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	4 / 103 (3.88%)	3 / 103 (2.91%)	4 / 136 (2.94%)
occurrences (all)	5	3	4
Abdominal distension			
subjects affected / exposed	6 / 103 (5.83%)	6 / 103 (5.83%)	1 / 136 (0.74%)
occurrences (all)	7	7	1
Abdominal pain			

subjects affected / exposed	5 / 103 (4.85%)	4 / 103 (3.88%)	3 / 136 (2.21%)
occurrences (all)	5	5	4
Abdominal pain upper			
subjects affected / exposed	9 / 103 (8.74%)	5 / 103 (4.85%)	2 / 136 (1.47%)
occurrences (all)	14	7	2
Constipation			
subjects affected / exposed	29 / 103 (28.16%)	24 / 103 (23.30%)	6 / 136 (4.41%)
occurrences (all)	34	30	7
Diarrhoea			
subjects affected / exposed	28 / 103 (27.18%)	29 / 103 (28.16%)	16 / 136 (11.76%)
occurrences (all)	49	46	23
Dyspepsia			
subjects affected / exposed	13 / 103 (12.62%)	8 / 103 (7.77%)	4 / 136 (2.94%)
occurrences (all)	19	13	5
Eructation			
subjects affected / exposed	10 / 103 (9.71%)	6 / 103 (5.83%)	1 / 136 (0.74%)
occurrences (all)	12	9	1
Flatulence			
subjects affected / exposed	5 / 103 (4.85%)	5 / 103 (4.85%)	3 / 136 (2.21%)
occurrences (all)	8	6	3
Gastrooesophageal reflux disease			
subjects affected / exposed	9 / 103 (8.74%)	8 / 103 (7.77%)	0 / 136 (0.00%)
occurrences (all)	13	9	0
Nausea			
subjects affected / exposed	50 / 103 (48.54%)	46 / 103 (44.66%)	24 / 136 (17.65%)
occurrences (all)	97	89	30
Vomiting			
subjects affected / exposed	23 / 103 (22.33%)	11 / 103 (10.68%)	6 / 136 (4.41%)
occurrences (all)	46	17	6
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 103 (0.97%)	3 / 103 (2.91%)	5 / 136 (3.68%)
occurrences (all)	1	3	5
Oropharyngeal pain			

subjects affected / exposed	4 / 103 (3.88%)	4 / 103 (3.88%)	7 / 136 (5.15%)
occurrences (all)	4	5	7
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	6 / 103 (5.83%)	3 / 103 (2.91%)	1 / 136 (0.74%)
occurrences (all)	6	3	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 103 (0.97%)	3 / 103 (2.91%)	5 / 136 (3.68%)
occurrences (all)	1	3	5
Insomnia			
subjects affected / exposed	2 / 103 (1.94%)	2 / 103 (1.94%)	1 / 136 (0.74%)
occurrences (all)	2	2	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 103 (3.88%)	5 / 103 (4.85%)	10 / 136 (7.35%)
occurrences (all)	6	5	10
Back pain			
subjects affected / exposed	8 / 103 (7.77%)	7 / 103 (6.80%)	10 / 136 (7.35%)
occurrences (all)	8	7	11
Infections and infestations			
Bronchitis			
subjects affected / exposed	2 / 103 (1.94%)	1 / 103 (0.97%)	9 / 136 (6.62%)
occurrences (all)	2	2	12
Gastroenteritis			
subjects affected / exposed	6 / 103 (5.83%)	4 / 103 (3.88%)	4 / 136 (2.94%)
occurrences (all)	6	5	6
Influenza			
subjects affected / exposed	7 / 103 (6.80%)	8 / 103 (7.77%)	8 / 136 (5.88%)
occurrences (all)	7	9	9
Nasopharyngitis			
subjects affected / exposed	20 / 103 (19.42%)	16 / 103 (15.53%)	16 / 136 (11.76%)
occurrences (all)	27	22	26
Sinusitis			
subjects affected / exposed	4 / 103 (3.88%)	6 / 103 (5.83%)	8 / 136 (5.88%)
occurrences (all)	6	6	8

Upper respiratory tract infection			
subjects affected / exposed	7 / 103 (6.80%)	12 / 103 (11.65%)	13 / 136 (9.56%)
occurrences (all)	8	16	19
Urinary tract infection			
subjects affected / exposed	3 / 103 (2.91%)	3 / 103 (2.91%)	5 / 136 (3.68%)
occurrences (all)	3	3	11
Viral infection			
subjects affected / exposed	4 / 103 (3.88%)	4 / 103 (3.88%)	4 / 136 (2.94%)
occurrences (all)	5	4	4
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	20 / 103 (19.42%)	12 / 103 (11.65%)	5 / 136 (3.68%)
occurrences (all)	23	13	5

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 August 2015	1) Clarifications of adequate contraceptive measures in Canada (one of the exclusion criteria), data collection of history of gallbladder disease, thyroid disease events that must be sent for adjudication and addition of timelines for adjudication. 2) Addition of standardised assessment of injection site reactions was added.
27 September 2016	This amendment addressed comments raised by the FDA during the investigational new drug (IND) review and clarified trial procedures: 1) The title and design was changed to a "sixteen armed" trial, as operationally there are 16 arms 2) In addition to the pooled data, supportive statistical analyses of primary endpoint including separate placebo arms were added. Descriptive statistics/plots for both pooled and separate placebo arms were added 3) To evaluate the intention-to-treat (ITT) estimand, the definition of effectiveness (and efficacy) estimand was added 4) The primary imputation approach was kept, and the imputation model was updated. Notes on the number of imputations were added. Sensitivity analyses were replaced with more appropriate approaches including the suggestions from FDA 5) Definitions of "in-trial" and "on-treatment" observation periods were added in the statistical section. It was clarified that safety endpoints were evaluated using the on-treatment observation period and the in-trial observation period. 6) It was clarified that hypoglycaemic episodes were tabulated according to full American Diabetes Association (ADA) classifications of hypoglycaemic episodes 7) Thyroid neoplasms were initially to be adjudicated centrally for the trial, but as the number of thyroid neoplasms was subsequently expected to be low, all trial procedures related to collection and central reading of thyroid pathology slides were removed 8) Retention of site files was changed to 15 years to comply with updated Novo Nordisk Standard Operating Procedure 9) Minor clarifications and correction of inconsistencies.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported